Adrenal And Dhea

Aralia Quinquefolia, Ashwagandha, Avena Sativa, Carduus Marianus, Dhea, Glandula Suprarenalis Suis, L-arginine, Natrum Muriaticum, Phosphoricum Acidum, Rhodiola.


Problen
Human Otc Drug
NDC 43853-0020
Adrenal And Dhea also known as Aralia Quinquefolia, Ashwagandha, Avena Sativa, Carduus Marianus, Dhea, Glandula Suprarenalis Suis, L-arginine, Natrum Muriaticum, Phosphoricum Acidum, Rhodiola. is a human otc drug labeled by 'Problen'. National Drug Code (NDC) number for Adrenal And Dhea is 43853-0020. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Adrenal And Dhea drug includes American Ginseng - 3 [hp_X]/30mL Arginine - 6 [hp_X]/30mL Avena Sativa Flowering Top - 3 [hp_X]/30mL Milk Thistle - 3 [hp_X]/30mL Phosphoric Acid - 200 [hp_C]/30mL Prasterone - 6 [hp_X]/30mL Rhodiola Kirilowii Root - 3 [hp_X]/30mL Sodium Chloride - 30 [hp_C]/30mL Sus Scrofa Adrenal Gland - 12 [hp_X]/30mL Withania Somnifera Root - 3 [hp_X]/30mL . The currest status of Adrenal And Dhea drug is Active.

Drug Information:

Drug NDC: 43853-0020
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Adrenal And Dhea
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Aralia Quinquefolia, Ashwagandha, Avena Sativa, Carduus Marianus, Dhea, Glandula Suprarenalis Suis, L-arginine, Natrum Muriaticum, Phosphoricum Acidum, Rhodiola.
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Problen
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AMERICAN GINSENG - 3 [hp_X]/30mL
ARGININE - 6 [hp_X]/30mL
AVENA SATIVA FLOWERING TOP - 3 [hp_X]/30mL
MILK THISTLE - 3 [hp_X]/30mL
PHOSPHORIC ACID - 200 [hp_C]/30mL
PRASTERONE - 6 [hp_X]/30mL
RHODIOLA KIRILOWII ROOT - 3 [hp_X]/30mL
SODIUM CHLORIDE - 30 [hp_C]/30mL
SUS SCROFA ADRENAL GLAND - 12 [hp_X]/30mL
WITHANIA SOMNIFERA ROOT - 3 [hp_X]/30mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 May, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:ProBLEN
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:8W75VCV53Q
94ZLA3W45F
MA9CQJ3F7F
U946SH95EE
E4GA8884NN
459AG36T1B
Y5M0NZV54F
451W47IQ8X
398IYQ16YV
V038D626IF
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
43853-0020-130 mL in 1 BOTTLE, SPRAY (43853-0020-1)09 May, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Temporarily supports the body to rebalance adrenal and dhea output. symptoms of imbalanced adrenal and dhea may include: low energy, depression, anxiety, dry eyes, skin, and hair, loss of head hair.*

Product Elements:

Adrenal and dhea aralia quinquefolia, ashwagandha, avena sativa, carduus marianus, dhea, glandula suprarenalis suis, l-arginine, natrum muriaticum, phosphoricum acidum, rhodiola. alcohol water american ginseng american ginseng withania somnifera root withania somnifera root avena sativa flowering top avena sativa flowering top milk thistle milk thistle prasterone prasterone sus scrofa adrenal gland sus scrofa adrenal gland arginine arginine sodium chloride chloride ion phosphoric acid phosphoric acid rhodiola kirilowii root rhodiola kirilowii root

Indications and Usage:

Uses: temporarily supports the body to rebalance adrenal and dhea output. symptoms of imbalanced adrenal and dhea may include: low energy, depression, anxiety, dry eyes, skin, and hair, loss of head hair.*

Warnings:

Warnings: not for use on children. if symptoms continue recur, or if sleeplessness persists continuously for more than two weeks, consult a physician. as with all medicines, if you are pregnant or breast feeding, consult a health professional before using this product. keep out of the reach of children. in case of overdose, get medical help or contact a poison control center right away. keep out of the reach of children.

Dosage and Administration:

Directions: adults: hold the spray-top close to your open mouth and spray twice directly under your tongue, three times a day. some people notice improvement within two or three weeks, others take longer.

Package Label Principal Display Panel:

Ndc: 43853-0020-1 adreno pro homeopathic organotherapy 1.0 fl oz (30ml) 20% alcohol 1 oz. bottle label temporarily supports the body to rebalance adrenal and dhea output. symptoms of imbalanced adrenal and dhea may include: low energy, depression, anxiety, dry eyes, skin, and hair, loss of head hair.*

Further Questions:

Distributed by: problen (888) 326-2121 3021 ridge rd., rockwall, tx 75032 questions or comments: www.problen.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.